Pharmacokinetics of a THIOMAB™ antibody drug conjugate (TDC): DMUC4064A in a phase 1 study with platinum-resistant ovarian cancer

被引：1
|
作者：
Garg, Amit
She, Gaohong
Donatello, Ian
Kagedal, Matts
Leipold, Douglas D.
Saad, Ola
Liu, Joyce
Moore, Kathleen
Hamilton, Erika
Burris, Howard
Wang, Judy
Birrer, Michael
Humke, Eric
Girish, Sandhya
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT092
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF A THIOMAB™ ANTIBODY DRUG CONJUGATE: DMUC4064A IN A PHASE I STUDY OF PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER.
    Wang, B.
    Kagedal, M.
    Leipold, D.
    Saad, O.
    Garg, A.
    Girish, S.
    Humke, E.
    Moore, K.
    Hamilton, E.
    Howard, B.
    Wang, J.
    Birrer, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S75 - S75
  • [2] Targeting MUC16 with the THIOMAB™-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study
    Moore, Kathleen
    Hamilton, Erica P.
    Burris, Howard A.
    Barroilhet, Lisa M.
    Gutierrez, Martin
    Wang, Judy S.
    Patel, Manish R.
    Birrer, Michael J.
    Flanagan, W. Mike
    Wang, Yulei
    Garg, Amit
    Lu, Xuyang
    Vaze, Anjali
    Amin, Dilip
    Leipold, Douglas
    Commerford, S. Renee
    Humke, Eric W.
    Liu, Joyce F.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Targeting MUC16 with the THIOMAB™-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study
    Liu, Joyce F.
    Moore, Kathleen N.
    Wang, Judy S.
    Patel, Manish
    Birrer, Michael J.
    Hamilton, Erika
    Barroilhet, Lisa
    Flanagan, William M.
    Wang, Yulei
    Garg, Amit
    Lu, Xuyang
    Vaze, Anjali
    Amin, Dilip
    Leipold, Doug
    Commerford, S. Renee
    Humke, Eric W.
    Burris, Harold A.
    CANCER RESEARCH, 2017, 77
  • [4] An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
    Liu, Joyce
    Burris, Howard
    Wang, Judy S.
    Barroilhet, Lisa
    Gutierrez, Martin
    Wang, Yulei
    Vaze, Anjali
    Commerford, Renee
    Royer-Joo, Stephanie
    Choeurng, Voleak
    Humke, Eric
    Moore, Kathleen
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 473 - 480
  • [5] PHARMACOKINETICS OF AN ANTIBODY-DRUG CONJUGATE ( ADC) DMUC5754A IN A PHASE I STUDY WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC) OR UNRESECTABLE PANCREATIC CANCER (PANC)
    Xu, J.
    Zhang, R.
    Saad, O.
    Liu, J. F.
    Moore, K. N.
    Burris, H. A., III
    Humke, E.
    Poon, K. Achilles
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S34 - S35
  • [6] Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
    Liu, J. F.
    Moore, K. N.
    Birrer, M. J.
    Berlin, S.
    Matulonis, U. A.
    Infante, J. R.
    Wolpin, B.
    Poon, K. A.
    Firestein, R.
    Xu, J.
    Kahn, R.
    Wang, Y.
    Wood, K.
    Darbonne, W. C.
    Lackner, M. R.
    Kelley, S. K.
    Lu, X.
    Choi, Y. J.
    Maslyar, D.
    Humke, E. W.
    Burris, H. A.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2124 - 2130
  • [7] Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.
    Liu, Joyce
    Moore, Kathleen
    Birrer, Michael
    Berlin, Suzanne
    Matulonis, Ursula
    Infante, Jeffrey
    Xi, Jian
    Kahn, Robert
    Wang, Yulei
    Wood, Katie
    Coleman, Daniel
    Maslyar, Daniel
    Humke, Eric
    Burris, Howard
    CANCER RESEARCH, 2013, 73 (08)
  • [8] PHARMACOKINETICS (PK) OF ANTI-MSLN ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH UNRESECTABLE PANCREATIC OR PLATINUM-RESISTANT OVARIAN CANCER IN A PHASE I STUDY.
    Samineni, D.
    Li, C.
    Nazzal, D.
    Maslyar, D.
    Li, D.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S46 - S46
  • [9] Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
    Weekes, Colin D.
    Lamberts, Laetitia E.
    Borad, Mitesh J.
    Voortman, Johannes
    McWilliams, Robert R.
    Diamond, Jennifer R.
    de Vries, Elisabeth G. E.
    Verheul, Henk M.
    Lieu, Christopher H.
    Kim, George P.
    Wang, Yulei
    Scales, Suzie J.
    Samineni, Divya
    Brunstein, Flavia
    Choi, YounJeong
    Maslyar, Daniel J.
    Colon-Otero, Gerardo
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (03) : 439 - 447
  • [10] PHARMACOKINETICS OF ANTIBODY-DRUG CONJUGATE (ADC)-DNIB0600A IN A PHASE I STUDY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (OC)/NON-SMALL CELL LUNG CANCER (NSCLC).
    Xu, J.
    Burris, H., III
    Gordon, M.
    Gerber, D.
    Choi, Y.
    Lin, K.
    Maslyar, D.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S32 - S32
12345